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A B S T R A C T
Malaria remains one of the most deadly diseases threatening humankind and is still affecting a signiﬁ-
cant proportion of the world population, especially in Africa. Chemotherapy is a vital component of the
ﬁght against the disease and new antimalarial agents are urgently needed to curb the spread of malaria
parasites that are resistant to existing drugs. The natural product tryptanthrin is known for its wide range
of activities, including antiplasmodial activity, but its poor solubility has undermined its development
as potent antimicrobial and antiprotozoan agent. The aim of this work was to synthesize analogues of
tryptanthrin and to evaluate their antiplasmodial activity against the asexual and sexual blood stages of
Plasmodium falciparum. Our results suggest that most tryptanthrin analogues retained their antiplasmodial
activity against chloroquine-sensitive and chloroquine-resistant malaria parasites in the nanomolar range
(30–100 nM). The antiplasmodial activity of the most active compound NT1 (IC50: 30 nM; SI: 155.9) was
similar in both strains and close to that of chloroquine (IC50: 20 nM) on the sensitive strain. The
antiplasmodial activity was improved with derivatization, thus pointing out the necessity to explore
tryptanthrin using medicinal chemistry approaches. Ten (10) of the tested derivatives met the criteria,
allowing for advancement to animal testing, i.e., SI > 100 and IC50 < 100 nM. In addition to their activity
on the asexual stages, tryptanthrin and two selected derivatives (NT1 and T8) prevented the matura-
tion of gametocytes at their IC90 concentrations, indicating a transmission-blocking potential. Moreover,
NT1 was able to impair gametogenesis by reducing the exﬂagellation of microgametes by 20% at IC90,
while tryptanthrin and T8 had no inﬂuence on exﬂagellation. The results of this study conﬁrm that
tryptanthrin and its derivatives are potential antimalarial candidateswith abilities to kill the intraerythrocytic
asexual stages and prevent the formation of sexual stages of the parasite.
© 2015 The Authors. Published by Elsevier Ltd on behalf of Australian Society for Parasitology. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Malaria, a disease caused by protozoan parasites of the genus
Plasmodium, remains one of the most devastating diseases in the
world. Despite encouraging progress in the control of malaria, there
was an estimated 627,000malaria-related deaths worldwide in 2012.
Most of the estimated cases occurred in sub-Saharan Africa (90%),
with children under 5 years of age representing the most affected
group (77%). Out of the ﬁve human pathogenic Plasmodium species,
Plasmodium falciparum is the most virulent strain, responsible for
almost all malaria-related death cases in Sub-Saharan Africa (World
Health Organization, 2013). In the absence of an effective vaccine,
the use of chemotherapy represents the most important pillar of
malaria eradication besides vector control and prophylaxis. The
World Health Organization now advises to apply artemisinin com-
bination therapies (ACTs) as a new ﬁrst line treatment, which shows
very good clinical eﬃcacy, especially towards P. falciparum malaria
(World Health Organization, 2011). Despite the reduction of the pa-
rasite’s sensitivity to artemisinins that has been reported in South
East Asia, ACTs continue to cure patients as long as the partner drug
is still effective. Nevertheless, resistance has been reported against
both components of multiple ACTs in a province of Cambodia (World
Health Organization, 2013). To maintain strict control of the disease,
it is therefore crucial for humans to remain a step ahead of the
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malaria parasite by continually seeking for novel antimalarial com-
pounds to overcome drug-resistant malaria parasites. In this regard,
in vitro screens for compound activity constitute a key component
of antimalarial drug discovery programs. To properly treat malaria,
the new hit must be highly potent against the asexual blood stages
of both drug-sensitive and drug-resistant parasites and be able to
prevent parasite transmission to the mosquito.
Tryptanthrin (indolo-[2, 1-b]-quinazoline-6, 12-Dione) is an al-
kaloid originally isolated from Isatis tinctoria, a medicinal plant in
temperate climate zones which has been used since antiquity as a
source for indigo dye production (Honda et al., 1980; Seifert and
Unger, 1994; Lee et al., 2007). Tryptanthrin was also identiﬁed as
the active principle of a traditional Japanese herbal remedy used
to treat fungal infections (Honda and Tabata, 1979). Following these
discoveries, a number of biological activities have been reported for
tryptanthrin and its derivatives, including antibacterial activity
(Kataoka et al., 2001), particularly against Mycobacterium tubercu-
losis (Mitscher and Baker, 1998; Lee et al., 2007; Hwang et al., 2013),
and activities against the protozoan parasites Plasmodium falciparum
(Bhattacharjee et al., 2004), Leishmania donovani (Bhattacharjee et al.,
2002), Trypanosoma brucei (Scovill et al., 2002), and Toxoplasma gondii
(Krivogorsky et al., 2008). In addition, the inhibitory activities of
tryptanthrin against cyclooxygenase (COX)-2 (IC50 = 64 nM),
5-lipoxygenase (LOX) (IC50 = 0.15 μM), nitric oxide synthase (NOS),
and prostaglandin E(2) expression at the cellular level opened a vista
for a possible lead for anti-inﬂammatory agents (Jahng, 2013). Ac-
tivity against tumor and cancer cells has also been reported (Yu et al.,
2007, 2010; Yang et al., 2013) and tryptanthrin derivatives were re-
cently reported to inhibit indoleamine 2,3-dioxygenase with
therapeutic activity in Lewis Lung cancer (LLC) tumor-bearing mice
(Yang et al., 2013). However, tryptanthrin has not been exten-
sively taken into consideration for pharmaceutical development
because of its poor solubility. The aim of this study was to gener-
ate and synthesize tryptanthrin analogues with improved solubility
and to evaluate their antiplasmodial activity against the asexual and
sexual blood stages of P. falciparum in vitro.
2. Experimental section
2.1. Procedures for the synthesis of tryptanthrin derivatives
2.1.1. General synthesis of 8-substituted tryptanthrins from
5-R-isatins (R = Me, F, Cl, Br, NO2)
Method A: 8-R-isatin (0.011 mol) was suspended in 10–15 ml
dry pyridine. After addition of 5 drops of triethylamine and
2.2 g isatoic acid anhydride (MW = 163.13, 0.013 mol), the solu-
tion was heated to approximately 60 °C for 15 min. Then, 1.5 ml
diisopropylcarbodiimide was added, and the solution was heated
to reﬂux for an additional 15–20min. During reﬂuxing, the dark so-
lution gave a crop of yellow crystals. These were isolated by suction
and washed with cold methanol.
8-Bromotryptanthrin, 8-Bromo-indolo [2,1-b] quinazoline-
6,12-dione (T2)
Synthesis according to method A: From 2.9 g of 5-bromoisatin
(MW = 226, 0.013 mol).
Yield: 1.1 g, 51%, yellow crystals recrystallized from chloroform.
Mp.: 276 °C.
MS (Cl): 328.8 (15%), 327.8 (96.8), 326.8 (14.5), 325.8 (100), 299.8
(24.35), 297.8 (23.75), 247.8 (10.7), 218. 8 (18.9), 190.9 (44.1), 163.8
(15.6).
IR (KBr, cm−1): 3067.9 (w), 1731 (m), 1674 (vs), 1592 (m), 1458
(m), 1429 (w), 1338 (m), 1300 (m), 1262 (w), 1181 (m), 1127 (w),
1041 (w), 872 (w), 772 (m), 687 (w).
1H-NMR (CDCl3, ppm): 8.28 (d, J = 8.23 Hz, 1H), 8. 18 (dd,
J = 8.23 Hz, 1.5 Hz, 1H), 7.7 (“m”, 2H), 7.6 (“q”, 2H), 7.4 (“t”, 1H).
13C-NMR (d6-DMSO, ppm): 181.56, 157.98, 146.45, 145.15, 140.04,
135.7, 130.33, 130.3, 127.45, 127.43, 124.6, 123.47, 119.47, 119.28.
C15H7O2N2Br: calc.: C: 55.0, H: 2.1, O: 10, N: 8.8, Br: 24; found:
C: 54.73, H: 2.2, N: 8.52, Br: 23.44.
8-Chlorotryptanthrin, 8-Chloro-indolo [2,1-b] quinazoline-
6,12-dione (T7)
Synthesis according to method A: From 2.2 g of 5-chloroisatin
(MW = 181, 0.012 mol).
Yield: 1.3 g, 38%, yellow crystals recrystallized from acetone.
Mp.: 287 °C.
MS (CI): 282 (100), 283 (35.85), 284 (34.12), 285 (11.84), 254
(11.24), 226 (4.95), 191 (24.52), 164 (2.81).
IR (KBr, cm−1): 3069 (w), 1730 (s), 1674 (vs), 1594 (s), 1558 (m),
1459 (s), 1450 (w), 1341 (s), 1300 (s), 1263 (w), 1218 (w), 1182
(m), 1125 (m), 1042 (w), 915 (w), 877 (w), 843 (w), 772 (m), 742
(w), 787 (w). 1H-NMR (CDCl3, ppm): 8.55 (d, J = 8.98 Hz, 1H), 8.41
(dd, J = 8.23 Hz/1.5 Hz, 1H), 8.01 (d, J = 8.23 Hz, 1H), 7.84 (dt,
J = 6.73 Hz/1.5 Hz, 2H), 7.72 (dd, J = 8.98 Hz/2.25 Hz, 1H), 7.67 (t,
J = 6.5 Hz, 1H).
C15H7O2N2Cl: calc.: C: 63.8, H: 2.5, O: 11.3, N: 9.9, Cl: 12.4; found:
C: 63.8, H: 2.5, N: 9.9, Cl: 12.5.
8-Fluorotryptanthrin, 8-Fluoro-indolo [2,1-b] quinazoline-
6,12-dione (T6)
Synthesis according to method A: From 2.14 g of 5-ﬂuoroisatin
(MW = 165, 0.013 mol).
Yield: 1.9 g, 54%, yellow crystals recrystallized from 80 ml THF.
Mp.: 271.5 °C.
MS (CI, e/m): 267 (37.18), 266 (100), 238 (14.11), 210 (7.53), 148
(3.75), 130 (10), 120 (4. 82), 108 (21.93).
IR (KBr, cm−1): 1722 (s), 1687 (s), 1592 (w), 1558 (w), 1484 (s), 1456
(w), 1351 (m), 1305 (w), 1269 (w), 1232 (w), 1185 (w), 1135 (w), 1116
(w), 1040 (w), 890 (w), 836 (m), 770 (s), 703 (w), 684 (w).
1H-NMR (CDC13, ppm): 8.6 (dd, J = 8.98Hz/3.74 Hz, 1H), 8.4 (dd,
J = 8.22Hz/1.5 Hz, 1H), 7.99 (d, J = 8.2 Hz, 1H), 7.82 (dt, J = 8.23 Hz/
1.5 Hz, 1H), 7.65 (t, 7.48 Hz, 1H), 7.54 (dd, 6.73 Hz/2.99 Hz, 1H), 7.44
(dt, 8.97 Hz/2.99 Hz, 1H).
13C-NMR (CDCl3, ppm): 181.7, 162.35, 159.86, 157.87, 146.5,
144.28, 142.5, 135.22, 130.67 (d, 2JCF = 34.9 Hz), 127.54, 124.81
(d, 2JCF = 24.3 Hz), 124.15, 123.68, 123.33 (d, 2JCF = 7.7 Hz), 119.67 (d,
2JCF = 6.8 Hz), 112.05 (d, 2JCF = 25.26 Hz).
C15H7O2N2F: calc.: C: 67.66, H: 2.63, O: 12.03, N: 10.52, F: 7.14;
found: C: 67.86, H: 2.77, N: 10.71, F: 6.44
8-Methyltryptanthrin, 8-Methyl-indolo [2,1-b] quinazoline-
6,12-dione (T1)
Synthesis according to method A: From 2.1 g of 5-methylisatin
(MW = 161.3, 0.013 mol).
Yield: 2.4 g, 70%, yellow crystals recrystallized from acetone.
Mp.: 270.5 °C.
MS (CI, m/e): 261.9 (100%), 233.8 (24.14), 204.8 (15.5), 130.8
(3.33), 129.8 (3.22), 101.8 (6.15)
IR (KBr, cm−1): 3061 (w), 3029 (w), 2933 (w), 1724 (s), 1684 (vs),
1613 (w), 1593 (m), 1558 (w), 1482 (m), 1458 (m), 1340 (m), 1309
(m), 1297 (w), 1261 (w), 1227 (m), 1186 (w), 1154 (w), 1138 (m),
1041 (m), 947 (w), 886 (w), 830 (m), 796 (w), 774 (s), 705 (w), 688
(m), 659 (w).
1H-NMR (d6-DMSO, ppm): 8.33 (d, J = 8.23 Hz, 1H), 8.3 (d,
J = 7.5 Hz, 1H), 7.93 (s, 1H), 7.92 (s, 1H), 7.7 (“m”, 3H), 2.4 (s, 3H).
13C-NMR (d6-DMSO, ppm): 205.67, 182.6, 157.61, 146.55, 145.31,
144.05, 138.2, 136.75, 135.13, 129.87, 126.95, 124.85, 123.43, 122.4,
116.87, 20.55.
C16 H10O2N2: calc.: C: 73.1, H: 4.0, O: 12.0, N: 11.1; found: C: 73.15,
H: 3.78, N: 10.64.
8-Nitrotryptanthrin, 8-Nitro-indolo [2,1-b] quinazoline-6,12-
dione (T4)
Synthesis according to method A: From 2.2 g of 5-nitroisatin
(MW = 192, 0.011 mol).
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The solution was kept overnight in a refrigerator and the solid
was isolated by suction.
Yield: 0.7 g, 23%, crystals recrystallized from 100 ml THF.
Mp.: 298 °C.
MS (CI, e/m): 293.8 (21.55%), 292.7(100), 264.8 (21.6), 262.9 (24.
31), 218.8 (32.82), 190.8 (16.22), 164.8 (7.34).
IR (KBr, cm−1): 3089 (w), 3029 (w), 1734 (s), 1682 (vs), 1607 (s),
1590 (s), 1522 (s), 4660 (m), 1444 (m), 1341 (vs), 1324 (s), 1309
(m), 1300 (s), 1278 (vs), 1218 (w), 1194 (w), 1156 (w), 1125 (m),
1090), 1062 (w), 1039 (w), 951 (w), 923 (w), 889 (w), 853 (m), 839
(w), 803 (w), 784 (m), 747 (w), 726 (w), 690 (w), 660 (w), 626 (w).
1H-NMR (CDCl3, ppm): 8.85 (d, J = 8.98Hz, 1H), 8.75 (d, J = 2.24Hz,
1H), 8.69 (dd, J =8.98Hz, 2.24Hz, 1H), 8.47 (dd, J =7.48Hz, 1.49Hz, 1H),
8.06 (d, J = 7.48Hz, 1H), 7.9 (t, J = 1.49Hz, 1H), 7.73 (t, J = 7.6 Hz, 1H).
C15H7O4N3: calc.: C: 61.1, H: 2.0, O: 22.0, N: 14.1; found: C: 61.52,
H: 2.58, N: 14.13.
2.1.2. General synthesis of 8-substituted tryptanthrins from
2-chloro-3H-indol-3-one
Method B: 5-nitro-2-chloro-3H-indol-3-one (according to
Grimshaw and Begley, 1974).
1.9 g of 5-nitroisatin (MW = 192, 0.01mol) and 2.4 g (MW = 206,
0.012 mol) phosphorus pentachloride were reﬂuxed in 10 ml an-
hydrous benzene for several hours. The yellow solid slowly dissolved
to become a red liquid. After 3–4 h, the liquid was ﬁltrated over a
ﬁne glass frit under exclusion of moisture and left to crystallize. After
1 day at room temperature, deep red crystals of the precipitate ap-
peared. Those were ﬁltrated via suction and dried in high vacuum
for 3–5 h. Yield: 1.5 g, 75%.
Synthesis of 5-bromo 2-chloro-3H-indol-3-one
5-bromo 2-chloro-3H-indol-3-one was synthesized analogously.
General procedure of the synthesis of tryptanthrins by ring-
closing reaction of 5-nitro-2-chloro-3H-indol-3-one with several
anthranilic acids:
The 5-nitro-2-chloro-3H-indol-3-one or 5-bromo-2-chloro-3H-
indol-3-one resulting from the above procedure was suspended in
dry dimethylformamide and combined with a solution of 4-chloro-
2-aminobenzoic acid and 5-chloro-2-aminobenzoic acid or
2-aminoterephtalic acid or others in DMF. The darkening mixture
was stirred at room temperature. Then, the mixture was heated to
100–120 °C for 10–15min and a ring-closing reaction occurred, iden-
tiﬁed by decolorization and crystallization. The reaction was
monitored until completeness, which was controlled via thin layer
chromatography. After cooling, the crystals were separated by
suction. Depending on the different solubility of the compounds,
the addition of a second solvent such as acetic acid may be required.
2-Chloro-8-nitro-tryptanthrin, 2-Chloro-8-nitro-indolo [2,1-
b] quinazoline-6,12-dione (NT2)
Synthesis according to method B: 1.7 g of 2-amino-5-
chlorobenzoic acid (MW = 172, 0.01 mol) in 2.5 ml DMF and 1.92 g
(0.01 mol) 5-nitro-2-chloro-3H-indol-3-one in 2.5 ml DMF.
Yield: 0.96 g, recrystallization from 20 to 25 ml DMF. From the
mother liquor, a further 0.5 g of product can be obtained after cooling.
Total yield: 39%.
Mp./decomp.: 282 °C.
MS (CI, e/m): 329.0 (33.07), 328.1 (19.17), 327.1 (100), 299.2 (2.03),
283.2 (2.03), 282.1 (3.13).
IR (KBr, cm−1): 3336 (br), 3093 (w), 1730 (s), 1700 (s), 1615 (m),
1577 (w), 1523 (m), 1459 (w), 1414 (w), 1382 (w), 1344 (m), 1325
(w), 1284 (m), 1245 (m), 1128 (m), 1093 (w), 1064 (w), 1042 (w),
952 (w), 944 (w), 905 (w), 863 (w), 844 (w), 777 (w), 742 (w), 640
(w), 554 (w), 526 (w).
1H-NMR (CDCl3, ppm): 8.43 (d, J = 8.9 Hz, 1H), 8.75 (d, J = 2.25 Hz,
1H), 8.68 (dd, J = 2.24/8.9 Hz, 1H), 8.41 (d, J = 2.24 Hz, 1H), 7.99 (d,
J = 8.23, 1H), 7.83 (dd, J = 2.24/8.9 Hz, 1H).
3-Chloro-8-nitro-tryptanthrin, 3-Chloro-8-nitro-indolo [2,1-
b] quinazoline-6,12-dione (NT1)
Synthesis according to method B: 1.7 g of 2-amino-4-
chlorobenzoic acid (MW = 172, 0.01 mol) in 2.5 ml DMF and 1.92 g
(0.01 mol) 5-nitro-2-chloro-3H-indol-3-one in 2.5 ml DMF.
0.83 g, 25%, recrystallized from THF, brownish powder. When the
DMF mother liquor was allowed to stand at −18 °C, an additional
800 mg was isolated as crystals. Total yield: 50%.
Mp./decomp.: 228 °C.
IR (KBr, cm−1): 1729 (s), 1691 (vs), 1641 (w), 1604 (s), 1586 (s),
1527 (s), 1462 (s), 1415 (m), 1342 (s), 1313 (s), 1285 (s), 1215 (w),
1183 (m), 1128 (m), 1115 (m), 1094 (m), 1067 (s), 1044 (m), 951
(m), 905 (m), 842 (m), 780 (m), 743 (w), 705 (w), 682 (w), 641 (m),
626 (w), 554 (w).
MS (CI, e/m): 329 (1.08), 328 (1.28), 327 (1.9), 326 (2.67), 252
(0.82), 185 (2.89), 146.1 (6.73), 145.1 (100), 144.1 (16.84), 129.1 (7.89).
IR (KBr, cm−1): 1729 (s), 1691 (vs), 1641 (w), 1604 (s), 1586 (s),
1527 (s), 1462 (s), 1415 (m), 1342 (s), 1313 (s), 1285 (s), 1215 (w),
1183 (m), 1128 (m), 1115 (m), 1094 (m), 1067 (s), 1044 (m), 951
(m), 905 (m), 842 (m), 780 (m), 743 (w), 705 (w), 682 (w), 641 (m),
626 (w), 554 (w).
1H-NMR (CDCl3, ppm): 8.82 (d, J = 8.85Hz, 1H), 8.74 (d, J = 2.25Hz,
1H), 8.67 (ddt, J = 8.8 Hz/2.4 Hz, 1H), 8.37 (d, J = 8.4 Hz, 1H), 8.02 (d,
J = 2.0 Hz, 1H), 7.66 (dd, J = 8.4 Hz/2.0 Hz, 1H).
C15H6ClN3O4: calc.: C: 54.7; H: 1.82; N: 12.76; Cl: 10.6; found:
C: 55.0; H: 1.9; N: 13.0; Cl: 10.8.
2,3-Dimethoxy-8-nitro-tryptanthrin, 2,3-Dimethoxy-8-nitro-
indolo [2,1-b] quinazoline-6,12-dione (NT3)
Synthesis according to method B: 3.7 g of 5-nitro-2-chloro-3H-
indol-3-one (MW = 210, 0.0176 mol) in 15 ml DMF and 3.47 g 4,5-
dimethoxy-2-aminobenzoic acid (M = 197, 0.0176mol) in 5ml DMF.
Yield: 3.5 g, 56%, ﬁne needles. Puriﬁcation was performed by de-
coction of the crude product with acetone or THF, then the ﬁltrate
was crystallized by allowing to stand exposed to air.
Mp./decomp.: 328 °C.
MS (CI, e/m): 354 (30.73), 353 (100), 338 (4.82), 337 (5.49), 191
(3.07)
IR (KBr, cm−1): 3459 (br), 3090 (w), 1739 (s), 1686 (vs), 1636 (m),
1601 (m), 1585 (s), 1534 (m), 1503 (vs), 1453 (m), 1437 (w), 1421
(w), 1376 (m), 1344 (vs), 1301 (w), 1293 (s), 1250 (w), 1214 (m),
1186 (w), 1153 (w), 1117 (w), 1078 (w), 1042 (w), 990 (w), 927 (w),
872 (w), 851 (w), 779 (w), 771 (w), 745 (w), 667 (w).
1H-NMR (CDCl3, ppm): 8.81 (d, J = 8.65 Hz, 1H), 8.7 (d, J = 2.1 Hz,
1H), 8.64 (dd, J = 8.65 Hz/2.1 Hz, 1H), 7.7 (s, 1H), 7.42 (s, 1H), 4.06
(s, 3H), 4.02 (s, 3H).
C17H11O6N3: calc.: C: 57.7; H: 3.11, N: 11.9, found: C: 47.9; H: 3.0;
N: 12.1.
2-Chloro-8-bromo-tryptanthrin, 8-Bromo-2-chloro-indolo [2,1-
b] quinazoline-6,12-dione (BT2)
Synthesis according to method B: 0.5 g of 5-bromo-2-chloro-
3H-indol-3-one (M = 276, 0.00181 mol) in 7 ml DMF and 310 mg
4-chloro-anthranilic acid (MW = 171.6, 0.00181 mol). Puriﬁcation
was performed by washing with acetone and recrystallizing from
200 ml THF.
Yield: 390 mg, 59%, yellow crystals.
Mp.: 304 °C.
MS (CI, e/m): 364 (20.9), 363 (24.65), 362 (100), 361 (18.82), 360
(69.31), 334 (10.07), 332 (7.75), 225 (4.24).
IR (KBr, cm−1): 3349 (br), 3069 (w), 1731 (vs), 1674 (vs), 1648
(m), 1587 (m), 1456 (s), 1431 (w), 1332 (m), 1298 (m), 1262 (m),
1211 (m), 1181 (m), 1131 (w), 1084 (w), 1036 (w), 943 (w), 905
(w), 845 (s), 782 (w), 748 (m), 707 (w), 645 (w), 616 (w), 560 (w).
C15H6O2N2BrCl: calc.: C: 49. 85, H: 1.6, N: 7.8, Br: 22.0, Cl: 9.7,
found: C: 49.6; H: 1.8; N: 7.4; Br 21.8; Cl: 9.7.
3-Chloro-8-bromo-tryptanthrin, 8-Bromo-3-chloro-indolo [2,1-
b] quinazoline-6,12-dione (BT1)
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Synthesis according to method B: 0.5 g of 5-bromo-2-chloro-
3H-indol-3-one (M = 276, 0.00181 mol) in 7 ml DMF and 0.310 g
3-chloro-anthranilic acid (MW = 171.6, 0.00181 mol). Recrystalli-
zation from 100 ml dioxane.
Yield: 390 mg, 59%, yellow crystals.
Mp.: 303 °C.
MS (CI, e/m): 363.6 (20.92), 363.6 (21.15), 362.6 (100), 360.6
(16.74), 359.6 (69.05), 333.6 (16.56), 331.7 (12.74), 252.9 (5.15), 224.7
(13.49).
IR (KBr, cm−1): 3000 (w), 3100 (w), 1734 (s), 1675 (vs), 1584 (s),
1455 (m), 1431 (w), 1419 (w), 1338 (m), 1300 (m), 1274 (w), 1212
(w), 1181 (s), 1133 (w), 1117 (w), 1072 (w), 1038 (w), 943 (w), 900
(w), 888 (w), 842 (w), 778 (w), 741 (w), 702 (w), 688 (w), 634 (w).
C15H6O2N2BrCl: calc.: C: 49.85, H: 1.6, N: 7.8, Br: 22.0, Cl: 9.7, found
C: 49.9; H: 1.9; N: 8.4; Br: 21.16; Cl: 9. 8.
2,3-dimethoxy-8-bromo-tryptantrin, 8-Bromo-2,3-dimethoxy-
indolo[2,1-b]quinazoline-6,12-dione (BT3)
Synthesis according to method B: 0.5 g 5-bromo-2-chloro-3H-
indol-3-one (MW = 276, 0.00181 mol) in 4 ml benzene and 0.36 g
of 4,5-dimethoxyanthranilic acid in 2 ml DMF.
Yield: 310 mg, 44%, orange needles obtained by recrystalliza-
tion from DMF (relatively low solubility, 150 mg in 20 ml).
Mp.: 332 °C
MS (CI, e/m): 389 (21.8), 388 (100), 387 (24.9), 386 (86. 78), 373
(17.03), 345 (6.96), 308 (5.17).
IR (KBr, cm−1): 3000 (w), 3100 (w), 1720 (s), 1681 (s), 1627 (w),
1586 (m), 1547 (w), 1502 (s), 1473 (w), 1456 (s), 1437 (s), 1422 (s),
1375 (s), 1338 (m), 1309 (s), 1279 (m), 1249 (m), 1216 (s), 1183
(s), 1119 (m), 1075 (w), 1051 (w), 1041 (w), 1022 (w), 994 (s), 869
(m), 838 (m), 786 (m), 770 (m), 661 (w), 600 (w), 538 (w), 509 (m),
418 (m).
1H-NMR (CDCl3, ppm): 8.49 (d, J = 8.5 Hz, 1H), 7.97 (d, J = 2.0 Hz,
1H), 7.8 (dd, J = 8.5 Hz/2.0 Hz, 1H), 7.73 (s, 1H), 7.4 (s, 1H), 4.04 (s,
3H), 4.0 (s, 3H).
8-Nitro-tryptanthrin-3-carboxylic acid, 8-Nitro-6,12-dioxo-
6,12-dihydro-indolo[2,1-b]quinazoline-3-carboxylic acid (NT4)
Synthesis according to method B: 5-nitro-2-chloro-3H-indol-3-
onewas synthesized from3.84 g of 5-nitroisatin (MW = 192, 0.02mol)
in 20ml benzene and 4.25 g phosphorous pentachloride (MW = 206,
0.02mol + 15%) and was then totally evaporated and dried in high
vacuum. The total mass of crystalline 5-nitro-2-chloro-3H-indol-3-
one was dissolved in 30ml DMF, and 3.62 g aminoterephthalic acid
(MW = 181, 0.02mol) was added.
Yield: 2.9 g, 43%, a yellow crystalline powder was obtained by
recrystallization from DMF. This powder then was washed with
acetone by decoction and ﬁltered until small yellow cubes were
formed.
Mp.: > 340 °C.
MS (CI, e/m): 338.0 (20.94), 337.1 (100), 309.1 (10.28), 307.1
(17.41), 263.0 (18.53).
IR (KBr, cm−1): 3441 (br), 3111 (w), 2924 (w), 1749 (m), 1739
(m), 1689 (s), 1654 (w), 1636 (m), 1600 (s), 1533 (m), 1465 (w), 1437
(w), 1417 (w), 1383 (w), 1346 (m), 1281 (s), 1259 (m), 1233 (m),
1183 (w), 1129 (w), 1111 (w), 1078 (w), 1057 (w), 1040 (w), 932
(w), 868 (w), 765 (m), 686 (w), 676 (w).
1H-NMR (DMSO, ppm): 8.73 (dd, J = 8.9 Hz/2.25 Hz, 1H), 8.68 (d,
J = 8.23 Hz, 1H), 8.57 (d, J = 2.25 Hz, 1H), 8.45 (d, J = 8.22 Hz, 1H), 8.38
(1H), 8.22 (dd, J = 1.5 Hz/8.23 Hz, 1H) C16H7O6N3: calc.: C: 56.9, H:
2.07, N: 12.46, found: C: 56.9; H: 2.0; N: 12.0.
8-Bromo-tryptanthrin-3-carboxylic acid, 8-Bromo-6,12-dioxo-
6,12-dihydro-indolo[2,1-b] quinazoline-3-carboxylic acid (BT4)
Synthesis according to method B: 1 g 5-bromo-2-chloro-3H-
indol-3-one (MW = 243, 0.0041 mol) in 7 ml DMF and 0.745 g
2-aminoterepthalic acid (MW = 181.15, 0.0041 mol).
Yield: 0.64 g, 42%, yellow crystals obtained by recrystallization
of 1.3 g in 30 ml DMF, then puriﬁed by decoction in acetone.
MS (CI, e/m): 373.1 (34.03), 372 (100), 371.1 (4.65), 370 (90.3),
292.2 (20.79), 170.0 (22.2), 168.0 (53.4).
IR (KBr, cm−1): 3412 (br, m), 1737 (m), 1684 (vs), 1595 (m), 1558
(w), 1458 (m), 1429 (w), 1334 (w), 1300 (s), 1255 (w), 1219 (w),
1186 (m), 1133 (w), 1051 (w), 933 (w), 854 (w), 780 (w), 761 (w),
683 (w), 632 (w).
1H-NMR (DMSO, ppm): 8.41 (“t”, J = 1.5 Hz, 2H), 8.34 (s, 1H), 8.18
(d, J = 8.23 Hz, 1H), 8.08 (s, 1H), 8.04 (dd, J = 8.18 Hz/1.5 Hz, 1H).
13C-NMR (DMSO, ppm): 181.6, 166.7, 157.8, 147.0, 146.0, 145.2,
140.5, 137.5, 131.14, 130.4, 128.32, 127.87, 126.7, 124.8, 120.1, 119.66.
2.1.3. Synthesis of esters and amides
8-Nitro-tryptanthrin-3-carboxylic acid methylester, 8-Nitro-
6,12-dioxo-6,12-dihydro-indolo[2,1-b] quinazoline-3-carboxylic
acid methyl ester (NT5)
0.34 g 8-nitro-tryptanthrin-3-carboxylic acid (MW = 338, 1mmol)
was suspended in 20 ml anhydrous DMF. 0.36 g oxalyl chloride
(MW = 126, 2.85 mmol, 2.85 eq.) was dissolved in anhydrous
diethylether and added dropwise to the DMF solution. Foaming and
gas formation was observed. After 45 min stirring at room temper-
ature, the mixture was heated to 70–80 °C, whereby ether was
evaporated. After 1 h at this temperature, a clear solution has formed.
Then, 10 ml anhydrous methanol and 3 ml pyridine were added.
Under heat generation, precipitation can be observed. The precip-
itate was ﬁltrated by suction and recrystallized from acetone. Hereby,
only about half of the yellow solid dissolves, the rest being hardly
soluble. The suspension was then ﬁltrated and the acetone extract
was further concentrated via rotary evaporator.
Yield: 280 mg, 80%, yellow ﬂake-like crystals.
MS (CI, e/m): 351.8 (23.72), 350.8 (100), 320.9 (50.91), 319.8
(80.63), 291.9 (19.47), 276.9 (10.1)
IR (KBr, cm−1): 3100 (w), 3087 (w), 3077 (w), 1735 (s), 1683 (vs),
1600 (s), 1586 (s), 1464 (s), 1447 (m), 1423 (m), 1347 (s), 1311 (m),
1286 (vs), 1263 (m), 1236 (w), 1219(w), 1184 (w), 1119 (w), 1101
(w), 1082 (w), 1067 (w), 1043 (w), 955 (w), 933 (w), 869 (w), 762
(m), 747 (m), 708 (w), 685 (w).
1H-NMR (d6-Acetone, ppm): 8.82 (“dq”, 2.3 Hz/8.8 Hz, 2H), 8.65
(d, J = 2.3 Hz, 1H), 8.52 (“dt”, J = 1.5 Hz, 2H), 8.32 (“dt”, J 1.5 Hz, 1H),
3.99 (s, 3H).
8-Bromo-tryptanthrin-3-carboxylic acidmethylester, 8-Bromo-
6,12-dioxo-6,12-dihydro-indolo[2,1-b] quinazoline-3-carboxylic
acid methylester (BT5)
0.37 g 8-bromo-tryptantrhin-3-carboxylic acid (MW = 372,
1mmol) was suspended in 20ml anhydrous DMF and 40ml methy-
lene chloride. Upon cooling in an ice bath, 0.26 g oxalyl chloride
(MW = 162, 2mmol) was added dropwise, upon which foaming and
gas generation was observed. The ice bath was removed, and the
mixture was allowed to reach room temperature. After 30 min, the
methylene chloride was removed via rotary evaporation. After stir-
ring overnight, 10 ml methanol and 2 ml pyridine were added, and
the solution was stirred for a further 24 h. Then, the mixture was
poured in 10 ml of diluted NaOH solution. The resulting precipi-
tate was ﬁltrated over a suction ﬁlter and recrystallized from acetone.
Yield: 100 mg, 30%, ﬁne yellow powder.
MS (CI, e/m): 387.7 (3.56), 386.7 (17.9), 385.7 (100), 384.7 (18.9),
383.7 (94.90), 355.8 (12.88), 354.8 (40.53), 353.8 (7.42), 352.8 (42.82),
326.8 (13.05), 325.8 (5.84), 324.8 (12.9), 305.9 (25.2), 274.9 (13.43).
IR (KBr, cm−1): 3105 (w), 3056 (w), 2953 (w), 1734 (s), 1667 (vs),
1593 (s), 1558 (w), 1459(s), 1430 (m), 1338 (m), 1288 (s), 1240 (w),
1217 (w), 1184 (m), 1117 (w), 1097 (w), 1045 (w), 983 (w), 918
(w), 855 (w), 838 (w), 762 (s), 683 (w), 632 (w), 554 (w), 485 (w).
1H-NMR (CDCl3, ppm): 8.65 (d, J = 1.5 Hz, 1H), 8.52 (d, J = 8.3 Hz,
1H), 8.48 (d, J = 8.23 Hz, 1H), 8.27 (dd, J = 1.5 Hz/8.23 Hz, 1H), 8.02
(d, J = 2.5 Hz, 1H), 7.8827 (dd, J = 2.4 Hz/8.23 Hz, 1H), 3.99 (s, 3H).
3-Chloro-indolo [2,1-b] quinazoline-6,12-dione (T8)
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Preparation of 7-chloro-1H-3,1-benzoxazine-2,4-dione (7-
Chloroisatoic acid anhydride)
Five grams 4-chloro-2-amino-benzoic acid (0.03 mol,
MW = 171.58) was dissolved in 150 ml distilled water with 4.15 g
K2CO3. Within one hour, 4.05 g (3.7 ml) chloroformic acid ethylester
was dropped into this solution with intense stirring. Then, the so-
lution containing some solid particles was heated in a water bath
set at 50–60 °C for two hours. Then, the solution was acidiﬁed with
hydrochloric acid, whereby a mass of solid appeared. This solid was
isolated by suction. After drying in an exsiccator, this mass of product
containing 4-chloro-2-ethyloxycarbonylamino-benzoic acid (5.4 g)
was recrystallized from toluene.
1H-NMR (CDCl3, ppm): 10.21 (s, 1H), 8.57 (d, J = 1.05 Hz, 1H), 8.02
(d, J = 8.22 Hz, 1H), 7.017 (dd, J = 2.25 Hz/8.22 Hz, 1H), 4.24 (q,
J = 6.73 Hz, 2H), 1.33 (t, J = 7.48 Hz, 3H).
4.0 g of 4-chloro-2-ethyloxycarbonylamino-benzoic acidwas treated
with 30ml of thionylchloride andheated to reﬂux. Initially, all the solids
dissolved within 10min. During reﬂuxing, a mass of crystals, plate-
lets of product, appeared gradually. After 3.5 h, two thirds of
thionylchloride was removed by vacuum and the rest was swept over
a frit. The ﬁltrate contained less than 10% material. The crystals of
7-chloroisatoic acid anhydride present on the frit were dried in vacuo.
IR (KBr, cm−1): 3320 (w), 3181 (m), 2996 (w), 1782 (vs), 1764
(vs), 1708 (w), 1617 (s), 1599 (m), 1489 (w), 1474 (w), 1404 (m),
1346 (s), 1327 (w), 1266 (w), 1244 (m), 1083 (w), 1028 (s), 931 (w),
892 (w), 794 (w), 761 (w), 750 (w), 707 (w), 677 (w).
MS (CI): 198.2 (18.7), 197.2 (15.36), 182.2 (10.04), 180.2 (33.6),
155.2 (31.02), 154.2 (22.14), 153.2 (100), 128.1 (21.9), 126.1 (85.65).
Preparation of 3-chlorotryptanthrin
1.9 g of 4-Chloroisatoic acid (MW = 197, 0.0096 mol) and 1.47 g
isatine (MW = 147, 0.007 mol) was suspended in 10 ml dry pyri-
dine. After addition of three drops of triethylamine, the mixture was
heated at 50–60 °C for 15 min. Then, 1 ml diisopropylcarbodiimid
was added and the mixture was reﬂuxed. All solids gradually dis-
solved over an hour of heating and crystalline needles appeared.
During cooling, the mass became solid. The crystals were isolated
by suction, washed with methanol, and dried in vacuo. Yield: 1.2 g.
Recrystallization was performed with THF.
MS (CI): 285.0 (7.36%), 284.0 (35.04), 283.0 (19.96), 282.0 (100),
254.0 (14.15), 191.1 (21.28)
IR (KBr, cm−1): 3444 (br), 3090 (w), 2996 (w), 1728 (vs), 1696
(vs), 1646 (w), 1587 (s), 1460 (w), 1419 (w), 1350 (m), 1311 (s), 1192
(m), 1107 (w), 1070 (w), 1070 (w), 934 (m), 885 (w), 838 (w), 808
(w), 774 (w), 6751 (s), 682 (w).
1H-NMR (CDCl3, ppm): 8.45(d, J = 8.23 Hz, 1H), 8.3 (d, J = 8.5 Hz,
1H), 8.0 (s, 1H), 7.88 (m, 2H), 7.77 (d, J = 8.22 Hz, 1H), 7.48 (m, 1H)
13C-NMR (CDCl3, ppm): 182.3, 173.7, 157.3, 147.8, 146.2, 145.9,
139.8, 138.0, 130.0, 129.0, 128.9, 127.2, 124.9, 122.3, 117.1
7-Methyl-indolo [2,1-b] quinazoline-6,12-dione (T3)
4-Methyl/6-Methylisatin mixture of isomers: 16 g concen-
trated H2SO4 was diluted by addition into 400 ml distilled water.
Then, 30.5 g m-toluidin was added and themixture was heated until
complete dissolution of m-toluidin. Subsequently, 23.5 g chlo-
ralhydrate and 31.5 g hydroxylamine were added. This mixture was
boiled and a precipitate was obtained, isolated, and dried: 5.2 g, 52%.
The drymaterial was then slowly added into 20 g concentrated H2SO4
at 70 °C. During addition, the temperature rose to 85 °C. After cooling,
the dark mixture was added to 0.5 kg of ice. The red precipitate was
isolated and dried. This material is a mixture of isomers, consist-
ing of 4- and 6-methylisatin in approximately a 1:1 ratio. Yield: 4.5 g,
yellow powder. This material was recrystallized several times from
100 ml 8% NaOH and acidiﬁed to pH 3by addition of diluted HCl.
This material still contained 18% of other isomers. Several of these
batches were pooled. After recrystallization from ethanol, a sample
of 2.2 g of 4-methylisatin containing at least 10% of 6-methylisatin
was obtained.
1H-NMR (CDCl3): 7.3(d, 1H), 7.2(“t”, 1H), 6.85 (dd, 1H), 6.8 (d, 1H),
6.7 (d, 1H), 6.58 (d, 1H), 1.34 (s, 6H)
Transformation into 7-methyltryptanthrin
2.2 g of 4-methylisatin was condensed with 2.1 isatoic acid an-
hydride in 10 ml pyridine/5 drops NEt3, heated to 60 °C for 15 min.
Then, 1,5ml diisopropylcarbodiimide was added, themixture heated
to reﬂux for 30 min. After cooling, the precipitate was washed with
methanol and ether. Yield 1.25 g, 35%.
MS (CI): 261.9 (100%), 262.9 (18.4), 233.9 (25.6), 232.9 (6.77),
205.8 (7.7), 204.8 (15.6)
1H-NMR (CDCl3): 8.2 (m, 1H), 7.55 (m, 2H), 7.4 (m, 2H), 7.35 (d,
J = 8.2Hz, 1H), 6,93 (d, J = 8.2HZ, 1H) 2.47 (s, 3H)
3-Bromo-8-nitro-indolo [2,1-b] quinazoline-6,12-dione (NT6)
NT6 was condensed from 8-nitroisatin and the corresponding
isatoic acid anhydride, 7-bromo-1H-3,1-benzoxazine-2,4-dione 1
(R′ = 7-Br) according to Method A, itself obtained from 4-bromo-
2-amino-benzoic acid via 4-bromo-2-(ethoxycarbonylamino) benzoic
acid according to T8. Yield (after recrystallization from DMF): 36%.
MS (CI): 373.9 (11.71%), 372.9 (74.21), 371.8 (12.70), 370.8 (73.35),
328.9 (15.84), 327.9 (100), 326.9 (21.29), 325.9 (98.55)
1H-NMR (CDCl3) 8.82 (d, J = 8.98 Hz, 1H), 8.74 (d, J = 2.24 Hz, 1H),
8.67 (dd, J = 8.97 Hz/2.25 Hz, 1H), 8.57 (d, J = 2.25 Hz, 1H), 7.98 (dd,
J = 8.23 Hz/2.25 Hz, 1H), 7.90 (d, J = 8.23 Hz, 1H)
2.2. Evaluation of the antiplasmodial activity of tryptanthrin
derivatives
Compounds were screened for growth inhibition activity against
P. falciparum using the Malstat assay as described in the literature
(Makler and Hinrichs, 1993; Makler et al., 1993). Synchronized ring
stages of P. falciparum strains NF54 and Dd2 were plated in tripli-
cate in 96-well plates (200 μl/well) at a parasitemia of 1% in the
presence of the compounds dissolved in dimethyl sulfoxide (DMSO).
The IC50 concentration of each compound was determined as pre-
viously described (Aminake et al., 2011). The ﬁnal concentration of
DMSO in the assay was 0.5%.
2.3. Gametocyte production
Asexual cultures of P. falciparumNF54 parasites were used to seed
gametocyte cultures at 1–2% parasitemia and 5% hematocrit in a total
volume of 25 ml. The culture was then incubated at 37 °C under a
gas mixture of 5% O2, 5% CO2, and 90% N2. The culture medium (RPMI
medium with 25 mM HEPES, 50 mg/l hypoxanthine, 2 g/l sodium
bicarbonate, 10% human serum) was replaced daily for at least 14
days, with the medium and work surface heated to 37 °C. Once the
parasitemia increases to 5–10% after 3–4 days of culture, the asexual
stages became stressed and started to differentiate into stage II ga-
metocytes at day 5, stage III visible at day 9, stage IV visible at day
11, and stage V, with high levels of exﬂagellation, visible around day
14 or 15.
2.4. Gametocyte toxicity test
P. falciparum NF54 parasites were cultivated at high parasit-
emia to favor gametocyte formation as described above. Upon the
appearance of stage II gametocytes, 1 ml of culture was aliquoted
in triplicate in a 24-well plate in the presence of compounds at their
respective IC50 values. The gametocytes were cultivated for 7 days
and the medium was replaced daily. For the ﬁrst 48 h of cultiva-
tion, the gametocytes were treated with the test compounds and
afterwards the medium used for feeding was compound free. After
7 days, Giemsa-stained blood smears were prepared and the
gametocytemia was evaluated by counting the number of stage IV
and V gametocytes in a total number of 1000 erythrocytes.
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2.5. Exﬂagellation assay
From day 13 of culture, exﬂagellation was tested by withdraw-
ing 100 μl of gametocyte culture and mixing with 10 μl xanthurenic
acid (XA) 1 mM to activate the mature gametocytes. The mixture
was incubated for 15 min and centrifuged to pellet cells. Most of
the supernatant was removed and the cells were resuspended in
an equal pellet volume (RPMI mediumwith 25mMHEPES, 50 mg/l
hypoxanthine, 2 g/l sodium bicarbonate, 100 μM xanthurenic acid,
10% human serum). Then, 10 μl of the solution were placed on a
glass slide and covered by a cover slide. Exﬂagellation was ob-
served at a magniﬁcation of 10× and the culture was considered
suitable for the assay if at least 4 exﬂagellation centers per ﬁeld were
counted in the preparation. For the assay, the IC50 and IC90 concen-
trations were investigated against a control which was treated with
DMSO at a ﬁnal concentration of 0.5%. Two (2) milliliters of the
aliquots of mature gametocyte culture were transferred into two
different 25-cm2 ﬂasks. The compoundwas added in the ﬁrst culture
ﬂask and only DMSO was added in the second; the ﬁnal concen-
tration of DMSO in the two cultures was 0.5%. After an incubation
time of 15 min at 37 °C, an aliquot of 100 μl per culture ﬂask was
collected and the culture ﬂask was returned to the incubator for 24 h
incubation. The aliquot was activated with XA and prepared for mi-
croscopy as described above. The exﬂagellation centers were counted
in 30 ﬁelds. After 24 h incubation, another aliquot of 100 μl per
culture ﬂask was collected, activated with XA, and prepared for mi-
croscopy as described above. The experiment was repeated oncewith
a different culture seeded on a different day.
2.6. Evaluation of compounds cytotoxicity
The cytotoxicity of the compounds was evaluated using the MTT
assay (Mosmann, 1983). MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5
Diphenyltetrazoliumbromid) is taken up by living cells and con-
verted by mitochondrial dehydrogenases to a violet formazan that
cannot diffuse through cell membranes and crystallizes in vital cells.
The method was carried out with MCF-7 cells as previously de-
scribed (Aminake et al., 2011).
2.7. Hemolysis assay
Freshly prepared uninfected erythrocytes were rinsed using
culture medium and resuspended in the same medium at a ﬁnal
hematocrit of 5%. They were then plated in triplicates in a 96-well
plate. A two-fold serial dilution of the compounds was tested, start-
ing at 10 μM. Medium supplemented with 0.15% saponin was used
for the positive control and 0.5% DMSO was used for the negative
control. The plates were then placed in a sealed jar, ﬂushed with a
gas mixture of 5% O2, 5% CO2, and 90% N2, and incubated at 37 °C
for 48 h. After incubation, the plates were centrifuged at 800 g for
2 min and an aliquot of 100 μl of the supernatant was transferred
to a new 96-well microtiter plate. The absorbance of free hemo-
globin in the supernatant was measured at 550 nm.
2.8. Statistical analysis
The GraphPad prism software (GraphPad version 5 http://
www.graphpad.com/prism/prism.htm) was used for all the analy-
ses. The comparison of the activities of the tested compounds was
performed using one way ANOVA followed by a Tukey’s test to
compare the mean gametocytemia of the tested compounds against
the mean gametocytemia in the DMSO control as well as to compare
the mean relatives exﬂagellation centers observed after treat-
ment. The OD values obtained after the Malstat and cytotoxicity
assays were plotted against logarithmic concentrations of the com-
pounds and a dose–response curve was automatically generated;
the IC50 values were deduced using GraphPad Prism.
3. Results and discussion
3.1. Synthesis of tryptanthrin derivatives
The synthesis of our panel of substituted tryptanthrins relied on
some longer known methods that are complementary because
not all derivatives are equally accessible by diverse reactions. Me-
thod A (Scheme 1) comprises the reaction of substituted 1H-
Benzo[d][1,3]oxazine-2,4-diones 1 (isatoic acid anhydrides) with
isatines 2 (Mitscher et al., 1981; Bergman et al., 1985), a route not
fully exploited. This was applied to synthesize compounds T1–T7.
Isatoic acid anhydrides are generally not available commercially,
except for one or two compounds. To obtain 2-nitrotryptanthrin,
isatine and 6-Nitro-1H-benzo[d][1,3]oxazine-2,4-dione (=6-
nitroisatoic acid anhydride) were reacted in pyridine. For the
synthesis of 6-nitroisatoic acid anhydride, we applied a ring-
closing procedure of 2-ethoxycarbonylamino-5-nitro-benzoic acid
3 (R′ = 5-NO2) with the advantage of directly obtaining a
R´ R´
R
PCl5
Benzene, Reflux
R
R´
R
pyridine, reflux
R´
DCCDI, pyridine, reflux
1 23
4
5 76
Scheme 1. Synthesis of tryptanthrins.
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crystalline material from the solution during the reaction.
2-Nitrotryptanthrin is highly unstable and could not be used for bi-
ological experimentation. In several cases, this method gave low
yields, e.g., with 8-nitroisatine. Another approach (method B, Scheme
1) was therefore needed and resulted in the application of 2-Chloro-
3H-indol-3-ones 5. These compounds condense to tryptanthrins 4
in the presence of anthranilic acids 7.
This approach appeared to also be applicable in cases where low
yields were achieved with method A because of either the low re-
activity of the partners or the lengthy preparation of the isatoic acid
anhydrides. All isatines 6 gave 2-Chloro-3H-indol-3-ones by re-
ﬂuxing in benzene solution with phosphorus pentachloride.
Condensation with anthranilic acids is most yielding in DMF (formic
acid dimethylamide) or acetic acid dimethylamide solution because
the product is considerably more soluble than hydrocarbons. There
are a number of derivatives that were inaccessible by these two
methods. By this approach or with the simpler method of condens-
ing 2-Chloro-3H-indol-3-one with anthranilic acids, no derivatives
that were substituted at position 10 could be obtained. This may
arise from sterical considerations due to the neighborhood of the
oxygen of the amide group. The goal of obtaining derivatives with
better solubility was only partially achieved. Even the use of
tryptanthrin carboxylic acid and its esters resulted in low solubil-
ity substances, prompting the use of DMSO as a co-solvent. In the
future, some inclusion complexesmight be of relevance (Kumar et al.,
2011). The synthesis of esters and amides generally proceeded well
by the simple application of the bis-imidazolylcarbonyl-method.
Preparation by way of acid chlorides often does not yield much. The
application of methods with limited thermal stress seems to be ap-
propriate, e.g., the use of oxalylchloride in the preparation of acid
chloride, as seen in the preparation of esters.
3.2. Antiplasmodial activities of tryptanthrin derivatives
The antiplasmodial activity of tryptanthrin and 17 tryptanthrin
derivatives was evaluated on chloroquine (CQ)-sensitive and CQ-
resistant strains of P. falciparum using theMalstat assay. The parasites
were exposed to serial dilutions of the compounds at concentra-
tions ranging from 100 μM to 0.01 μM, and the half maximal
inhibitory concentrations (IC50) were determined by measuring the
activity of the parasite lactate dehydrogenase (Table 1). Tryptanthrin
was active against both the CQ-sensitive and CQ-resistant strains
of P. falciparum, with IC50 values of 288 nM and 114 nM, respec-
tively. Sixteen 16 of the nineteen tryptanthrin derivatives were active
against both strains of P. falciparum, with IC50 concentrations in the
nanomolar range (between 33 and 602 nM), among which NT1, T6,
BT1, and BT2 were at least 5 times more potent than tryptanthrin
on the CQ-sensitive strain and NT1 had the strongest effect on the
CQ-resistant strain (3.3 times more active than tryptanthrin). In this
study, CQ was used as a reference drug and was 13 times more
potent against CQ-sensitive strains when activities were com-
pared against the resistant strain. However, the difference in activity
between the two strains was not signiﬁcant for tryptanthrin and
its derivatives. Compounds NT4 and BT4 were considered to be not
effective (IC50 > 50 μM) and are all carboxylic acid derivatives with
the acidic moiety at position 3 (Fig. 1). This result suggests that the
addition of the carboxylic moiety at that position is not beneﬁcial
for the antiplasmodial activity. The introduction of carboxylic acid
into a biologically active compound that does not contain such a
group already led to a generally better solubility and to the ame-
lioration of the binding of the derivative to the target. However,
carboxylic acids are already highly ionized at physiological pH and
cannot cross biological membranes, which are permeable to non-
dissociatedmolecules or to molecules with a very distributed charge
(Bazzani and Wermuth, 2008). Therefore, the addition of a carbox-
ylic acid group in a small molecule that needs to cross biological
membranes to reach his target will tend to weaken the activity of
the parent compound (Bazzani and Wermuth, 2008). Neverthe-
less, the loss in initial activity of a compound because of the
introduction of a carboxylic acid group is often recovered by
Table 1
Antiplasmodial activities of tryptanthrin and its derivatives.
Code Substituents LogP Mean IC50 ± SD (μM) Mean CC50 ± SD (μM) Selectivity index (SI)
R2 R3 R7 R8 NF54 Dd2 MCF7 SI (NF54) SI (Dd2)
NT1 H Cl H NO2 3.2 0.033 ± 0.004 0.031 ± 0.005 5.15 ± 0.11 155.9 168.7
NT2 Cl H H NO2 3.2 0.129 ± 0.022 0.091 ± 0,013 12.47 ± 0.23 96.7 136.5
NT3 OCH3 OCH3 H NO2 2.2 0.283 ± 0.093 0.134 ± 0.047 15.17 ± 4.41 53.6 113.2
NT4 H COOH H NO2 2.4 NE NE >100 ND ND
NT5 H COOCH3 H NO2 2.7 0.167 ± 0.067 0.166 ± 0.036 11.98 ± 0.50 71.7 72.1
NT6 H Br H NO2 3.3 0.072 ± 0.023 0.101 ± 0.068 17.52 ± 0.77 243.3 174
T1 H H H CH3 3 0.085 ± 0.037 0.216 ± 0.116 >100 >1000 >400
T2 H H H Br 3.4 0.081 ± 0.008 0.095 ± 0.058 10.47 ± 1.52 129.3 110.2
T3 H H CH3 H 3 0.450 ± 0.098 0.602 ± 0.115 17.65 ± 0.30 39.2 29.3
T4 H H H NO2 2.5 0.106 ± 0.038 0.165 ± 0.055 4.78 ± 0.49 45.1 29
T6 H H H F 2.4 0.057 ± 0.010 0.100 ± 0.015 17.47 ± 0.65 306.5 175.6
T7 H H H Cl 3.3 0.095 ± 0.033 0.172 ± 0.018 27.18 ± 6.68 286.1 158.5
T8 H Cl H H 3.3 0.092 ± 0.003 0.165 ± 0.081 17.12 ± 4.26 186 103.5
BT1 H Cl H Br 4.1 0.036 ± 0.017 0.238 ± 0.080 2.38 ± 0.001 66 10
BT2 Cl H H Br 4.1 0.036 ± 0.024 0.123 ± 0.062 >100 >2000 >800
BT3 OCH3 OCH3 H Br 3 0.088 ± 0.041 0.761 ± 0.194 >100 >1000 >100
BT4 H COOH H Br 3.3 NE NE 71 ± 39.73 ND ND
BT5 H COOCH3 H Br 3.5 0.162 ± 0.093 0.287 ± 0.024 11.49 ± 5.42 70.9 40
TRYP H H H H 2.6 0.288 ± 0.087 0.114 ± 0.017 45.90 ± 0.70 159.4 318
CQ / / / / / 0.021 ± 0.002 0.294 ± 0.030 >100 >4000 >4000
TRYP: Tryptanthrin; CQ: Chloroquine; CC50: Cytotoxic Concentration 50; NE: Not effective. SI: Selectivity index (CC50/IC50). LogP of compoundswere calculatedwithMolinspiration
(http://www.molinspiration.com).
Fig. 1. Structure of tryptanthrin depicting substitution sites.
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carboxyl-derived functions such as esters, which protect the acid
function and can cross biological membranes (Bazzani andWermuth,
2008). This may explain the regain of activity that we noted in com-
pounds NT5 and BT5, in which the carboxylic acid group of
compounds NT4 and BT4 was replaced by a carboxylic acid methyl
ester. A mono-derivatization of tryptanthrin with halogens (chlo-
rine, bromine, ﬂuorine) or with nitro and methyl groups in position
8 (Fig. 1) led to an equal gain in activity of approximately three times
than the parent compound. There was no signiﬁcant difference in
the IC50 value of the concerned compounds (T1, T2, T4, T6, and T7).
The reason for that behavior might be an increase in the lipophilicity
of tryptanthrin (Prokop et al., 2004) and thus a favored passage of
the compounds through the biological membranes. Bymoving a sub-
stituent such as the methyl group from position 8 (T1) to position
7 (T3), we noticed a loss of activity of approximately 5-fold com-
pared to that of T1. This might suggest that the position 8 of
tryptanthrin is important in improving biological activity. This ob-
servation was previously made by Scovill et al. (2002), who showed
that 8-halogenated tryptanthrin had better anti-trypanosomal ac-
tivities. Yu et al. reported a better activity on cancer cells when
tryptanthrinwasmodiﬁed at position 8 (Yu et al., 2010) and recently,
modiﬁcations at position 8 have retained special attention when
evaluating antitubercular derivatives (Hwang et al., 2013). It is in-
teresting to note that moving the chlorine substituent from position
8 (T7) to position 3 (T8) retains the biological activity, suggesting
that derivatization at position 3 could also be of interest. Tri-
derivatization with nitro-groups (NT3) or bromine (BT3) at position
8 and methoxy-groups at both positions 2 and 3 did not improve
the activity of the 8-mono-derivatives (T2 and T4). A similar ob-
servation was made by Yu and colleagues, who found out that
dimethoxy derivatization of tryptanthrin did not enhance the growth
inhibitory activity in cancer cells (Yu et al., 2010). We further pre-
dicted the lipophilicity of tryptanthrin and its derivatives and the
predicted LogP values were in the range of 2.2 to 4.1. It is general-
ly accepted that compounds with LogP values between 1 and 4 have
a good permeability. It is therefore important to maintain the per-
meability when further optimization is considered. Based on these
data alone, NT1 emerged as the most suitable compound for further
studies: it was the most soluble compound in DMSOwith no visible
precipitate at a concentration of 10 mM and had an IC50 slightly
equivalent to the reference drug CQ. Our observations and data
suggest that tryptanthrin derivatives could be evaluated in in vivo
mouse models; however, there is a necessity to further improve the
solubility of tryptanthrin derivatives via either appropriate formu-
lation or chemical modiﬁcations.
3.3. Cytotoxicity of tryptanthrin derivatives
Tryptanthrin and its derivatives were subjected to cytotoxicity
testing against the human cell line MCF-7 to determine the speci-
ﬁcity of their antiplasmodial effect. Therefore, the MTT assay was
carried out to measure the mitochondrial activity of the MCF-7 cells
after drug exposure as an indicator of cell proliferation, and the cy-
totoxicity of the compounds was determined by calculating the
concentration that leads to in vitro 50% cytotoxicity (CC50). The data
obtained were used to calculate the selectivity index (SI, Table 1),
allowing the identiﬁcation of compounds with potential therapeu-
tic windows that are not toxic to human or mammalian cells. To
further investigate the compounds using the mouse model, it is
usually recommended that SI > 100 (Nwaka and Hudson, 2006).
Based on this criterion, only compounds NT1, NT2, NT6, T1, T2, T6,
T7, T8, BT2, BT3, and tryptanthrin can be considered for animal
studies (Table 1). Interestingly, compounds T1 and BT2 were the
safest molecules with SI values higher than 1000. While the
antiplasmodial activity of NT1 was only 1.3 to 3 times higher than
that of BT2 and T1, these two compounds were 20 times safer than
NT1 when tested on the sensitive strain. NT1 showed a strong
antiplasmodial activity on both the sensitive and resistant strains,
and despite its strong inhibition of MCF-7 cells, the SI was higher
than 100 for both strains of P. falciparum. The high safety of BT2 and
T1 is particularly important because it is sometimes necessary to
increase the compound’s dose to achieve suitable drug plasma con-
centrations and eﬃcacy in vivo during pre-clinical studies.
Compounds such as BT2 and T1 will have less limitation because
a higher dose of the molecule can be administered. Based on the
cytotoxicity results, T1 and BT2 should be considered alongside NT1
for optimization and potential pre-clinical studies. We further evalu-
ated the effect of tryptanthrin and its derivatives on red blood cell
integrity and we did not observe any signs of membrane disrup-
tion at 10 μM (data not shown).
3.4. Transmission blocking activity
Malaria eradication using chemotherapy will be very effective
if the transmission of the parasite from human to human via mos-
quito bites is prevented. Considerable efforts are currently devoted
to evaluating the early-stage gametocytocidal activity of the MMV
Malaria Box (Lucantoni et al., 2013; Sun et al., 2014), which is a col-
lection of 400 compounds with known activity against the asexual
stages of P. falciparum (Lucantoni et al., 2013; Sun et al., 2014). This
result highlights the importance of experimental veriﬁcation of early-
stage gametocytocidal activity in the development of new
antimalarial candidates. The effect of tryptanthrin and the deriva-
tives NT1, T8, epoxomicin, and chloroquine was investigated on the
development of stage II to stage V gametocytes. The results con-
ﬁrmed that nanomolar concentrations of the positive control
epoxomicin were able to fully eliminate the gametocytes in the
culture (Fig. 2), which is in accordance with previous ﬁndings on
the gametocytocidal activity of the proteasome inhibitor epoxomicin
(Czesny et al., 2009; Aminake et al., 2011, 2012). Furthermore, it was
shown that IC50 concentrations of chloroquine did not signiﬁ-
cantly affect gametocyte maturation, while IC90 concentrations led
to mature gametocyte reduction of up to 20%. It was further ob-
served that IC50 concentrations of tryptanthrin and T8 did not
signiﬁcantly affect the maturation of gametocytes even though the
culture treated with T8 had a very slightly reduced number of stage
IV/V gametocytes compared to the number of stage IV/V gameto-
cytes in the DMSO control. Interestingly, the IC50 concentration of
NT1, which was previously determined by theMalstat assay, reduced
the amount of mature gametocytes by approximately 40–50% (Fig. 2).
At IC90 concentrations, all three compounds (tryptanthrin, NT1, and
T8) were effective and a 100% killing of gametocytes was ob-
served for NT1 and T8. However, the IC90 value of T8 was four times
higher than that of NT1. The parent compound tryptanthrin did not
achieve a 100% killing of gametocyte with an IC90 concentration
(Fig. 2) that wasmore than 10 times higher than that of NT1, showing
a clear improvement in gametocytocidal activity due to the
derivation.
Another approach of the transmission blocking strategy is the
inhibition of exﬂagellation by mature stage V gametocytes, which
are directly responsible for parasite transmission from the human
host to the mosquito and are thus a target for transmission-
blocking interventions (Delves et al., 2013). Mature stage V
gametocytes, which are quiescent in the human blood stream, must
be ingested by the mosquito to complete the maturation process
and develop intomale or female gametes, thereby initiating themos-
quito stage of the parasite. However, themature stage V gametocytes
are resistant to most of the antimalarials affecting the asexual blood
stages (Kumar and Zheng, 1990; Noedl et al., 2003). The effect of
tryptanthrin, T8, and NT1 on the exﬂagellation of mature gameto-
cytes was investigated, and it was shown that neither tryptanthrin
nor T8 were able to signiﬁcantly inhibit the exﬂagellation of
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microgametes after 15min as well as after 24 h of incubation at their
IC90 concentrations (Fig. 3). Interestingly, it was shown that the IC90
concentrations of NT1 could achieve up to 20% reduction of exﬂag-
ellation, which is again an improvement in the transmission-
blocking activity due to the derivation of tryptanthrin to NT1.
4. Conclusion
We report the antiplasmodial activity of tryptanthrin deriva-
tives and their potential transmission-blocking activity. Our data
suggest that NT1 is the most interesting antiplasmodial candidate
of all the tryptanthrin derivatives that were tested. NT1 showed the
strongest activity in the asexual stages in drug-sensitive as well as
in drug-resistant P. falciparum parasites. Furthermore, NT1 exhib-
ited the potential to prevent the maturation of early- to late-stage
gametocytes as well as a potential to inhibit the exﬂagellation of
microgametes, thus making it a transmission-blocking drug can-
didate. Nevertheless, as with any in vitro screening report, the
compound activity data produced in this study will beneﬁt from ad-
ditional studies to specify the activity.
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Fig. 2. Inhibition of gametocyte maturation. Stage II gametocytes were incubated with compounds at IC50 and IC90 concentrations or with a 0.5% vol DMSO for 2 days. The
number of stage IV and V gametocytes was counted after 7 days and the gametocytemia of drug-treated cultures was correlated to the gametocytemia of the DMSO control
(normalized to 100%). The graphs represent the results of two independent experiments performed in triplicate. Asterisks represent a signiﬁcant difference between the
tested compounds and DMSO control, ***P < 0.001; **0.001 < P < 0.01; *P < 0.05. The bar labels represent the standard deviation.
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Fig. 3. Effect of selected tryptanthrin-based compounds on exﬂagellation. Compounds at IC50 concentrations or 1% vol DMSO were added to mature gametocyte cultures
24 h or 15 min prior to their activation with xanthurenic acid. The number of exﬂagellation centers was counted 15 min after activation; the number of centers was re-
corded and compared to the number of centers in the DMSO control. The graphs represent the results of two independent experiments. Mean ± SEM. *P < 0.05. The bar
labels represent the standard deviation.
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